Asian-Pacific contract research organization (CRO) Novotech has issued a report describing a record year for clinical trials, as defined by numbers of studies, investigators, and patient enrollment.
The “Asia-Pacific Industry Highlights 2019-2020” document, released during the annual JP Morgan Healthcare Conference in San Francisco, details the significant pool of patients in Asia, among other factors.
Novotech said the area also benefits from high-quality infrastructure, relatively low trial concentration and lower costs compared with trial programs in Europe or the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze